cathepsin

(redirected from Cathepsin S)
Also found in: Medical, Encyclopedia.
Related to Cathepsin S: Cathepsin L

ca·thep·sin

 (kə-thĕp′sĭn)
n.
Any of various enzymes found in animal tissue that catalyze the hydrolysis of proteins into smaller proteins.

[German Kathepsin, from Greek kathepsein, to digest : kat-, kata-, cata- + hepsein, to boil.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

cathepsin

(kəˈθɛpsɪn)
n
(Biochemistry) a proteolytic enzyme responsible for the autolysis of cells after death
[C20: from Greek kathepsein to boil down, soften]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

ca•thep•sin

(kəˈθɛp sɪn)

n.
any of a class of intracellular enzymes that break down protein in certain abnormal conditions and after death.
[1925–30; < Greek kathéps(ein) to digest]
ca•thep′tic (-tɪk) adj.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
Moreover, cathepsin S expression is regulated by the IRF-1 transcription factor that is suppressed by miR-31 [38].
Burden, "Cathepsin S: therapeutic, diagnostic, and prognostic potential," Biological Chemistry, vol.
Cathepsins in Human Obesity: Changes in Energy Balance Predominantly Affect Cathepsin S in Adipose Tissue and in Circulation.
Global Markets Direct's, 'Cathepsin S (EC 3.4.22.27) - Pipeline Review, H1 2016', provides in depth analysis on Cathepsin S (EC 3.4.22.27) targeted pipeline therapeutics.
The report provides comprehensive information on the Cathepsin S (EC 3.4.22.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Another proteinase that has been implicated in COPD pathogenesis is cathepsin S, a lysosomal acidic proteinase which is highly expressed by cells implicated in COPD pathogenesis including macrophages and dendritic cells [6].
We hypothesized that plasma concentrations of cathepsin S and cystatin C would differ between COPD patients, subjects with cough and sputum, and healthy smokers and nonsmokers.
Medivir AB (OMX:MVIR) (STO:MVIRB.ST), an emerging research-based pharmaceutical company, announced today the selection of its drug, MIV-247, as a candidate drug (CD) from its cathepsin S inhibitor project for the treatment of neuropathic pain.
According to the company, MIV-247, which is also entering non-clinical development, is a potent and highly selective inhibitor of cathepsin S, an enzyme shown to be important for the maintenance of the neuropathic pain state, through its action in releasing fractalkine (a pro-inflammatory protein) in areas of the spinal cord important for pain sensation.
The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses.
During the latest quarter, Celera received $3 million in revenue from the resale of its cathepsin S inhibitor program to a privately held drug development company.
Cathepsin S (CatS) belongs to the family of lysosomal cysteine proteases that are normally present in lysosomes.